# Pivotal bioVenture Partners Investment Advisor LLC

> Institutional holdings reported to the SEC as of Q2 2026 on Form 13F. CIK 1844645. Source: https://holderbook.com/funds/1844645-pivotal-bioventure-partners-investment-advisor-llc/

- Reported value: $307.8M
- Positions: 13
- Weight of the ten largest: 95.1%
- Filed: 2026-08-13

A 13F reports long US equity positions only. Short positions, bonds, foreign listings, private holdings and cash are not visible, so this is not the manager's whole book.

## Holdings

| Security | Ticker | Value | Shares | Weight | Quarters held |
|---|---|---|---|---|---|
| VAXCYTE INC | [PCVX](https://holderbook.com/stocks/PCVX/) | $82.9M | 1,425,470 | 26.9% | 23 |
| ARCUTIS BIOTHERAPEUTICS INC | [ARQT](https://holderbook.com/stocks/ARQT/) | $33.2M | 1,265,283 | 10.8% | 23 |
| TREVI THERAPEUTICS INC | [TRVI](https://holderbook.com/stocks/TRVI/) | $32.5M | 1,742,672 | 10.6% | 5 |
| AVALYN PHARMACEUTICALS INC | [AVLN](https://holderbook.com/stocks/AVLN/) | $31.8M | 966,792 | 10.3% | 1 |
| EVOMMUNE INC | [EVMN](https://holderbook.com/stocks/EVMN/) | $25.6M | 1,926,943 | 8.3% | 3 |
| MAPLIGHT THERAPEUTICS INC | [MPLT](https://holderbook.com/stocks/MPLT/) | $21.9M | 611,446 | 7.1% | 3 |
| OCULIS HOLDING AG | [OCS](https://holderbook.com/stocks/OCS/) | $20.9M | 1,506,250 | 6.8% | 14 |
| BIOAGE LABS INC | [BIOA](https://holderbook.com/stocks/BIOA/) | $16.0M | 653,374 | 5.2% | 8 |
| IMMUNOME INC | [IMNM](https://holderbook.com/stocks/IMNM/) | $15.5M | 732,512 | 5.0% | 4 |
| ZENAS BIOPHARMA INC | [ZBIO](https://holderbook.com/stocks/ZBIO/) | $12.5M | 490,766 | 4.0% | 8 |
| AVALO THERAPEUTICS INC | [AVTX](https://holderbook.com/stocks/AVTX/) | $8.0M | 434,033 | 2.6% | 2 |
| RALLYBIO CORP | [RLYB](https://holderbook.com/stocks/RLYB/) | $4.8M | 300,579 | 1.6% | 2 |
| RECURSION PHARMACEUTICALS IN | [RXRX](https://holderbook.com/stocks/RXRX/) | $2.2M | 595,518 | 0.7% | 7 |

## What the disclosed book did

Not the fund's return. This is the change in value of the positions disclosed on Form 13F, had they been left untouched, against SPY over the same quarter ends.

| Quarter | Book | Market | Difference | Priced |
|---|---|---|---|---|
| Q2 2026 | -1.9% | +14.8% | -16.8% | 100% |
| Q1 2026 | +11.2% | -4.6% | +15.8% | 99% |
| Q4 2025 | +38.1% | +2.4% | +35.7% | 100% |
| Q3 2025 | +18.0% | +7.8% | +10.2% | 86% |
| Q2 2025 | +9.8% | +10.5% | -0.7% | 99% |
| Q1 2025 | -24.0% | -4.6% | -19.4% | 100% |
| Q4 2024 | -18.1% | +2.1% | -20.2% | 98% |
| Q3 2024 | +25.8% | +5.4% | +20.4% | 100% |

## Quarter by quarter

| Quarter | Value | Positions |
|---|---|---|
| Q2 2026 | $307.8M | 13 |
| Q1 2026 | $279.8M | 13 |
| Q4 2025 | $258.7M | 12 |
| Q3 2025 | $173.0M | 10 |
| Q2 2025 | $161.3M | 12 |
| Q1 2025 | $123.6M | 11 |
| Q4 2024 | $148.1M | 11 |
| Q3 2024 | $168.5M | 11 |
| Q2 2024 | $130.1M | 10 |
| Q1 2024 | $155.6M | 11 |
| Q4 2023 | $394.2M | 13 |
| Q3 2023 | $250.7M | 13 |